Posted by Michael Wonder on 27 May 2025
Teva celiac disease candidate granted fast track designation by US FDA
27 May 2025 - Designation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celiac disease.
Teva Pharmaceutical Industries today announced that the US FDA granted fast track designation for investigational TEV-53408, an anti-IL-15 antibody, for the treatment of people with celiac disease on a gluten-free diet.
